These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

185 related items for PubMed ID: 29155873

  • 1. Short-term anti-proteinuric effect of tacrolimus is not related to preservation of the glomerular filtration rate in IgA nephropathy: A 5-year follow-up study.
    Yu MY, Kim YC, Koo HS, Chin HJ.
    PLoS One; 2017; 12(11):e0188375. PubMed ID: 29155873
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Randomized controlled trial of mycophenolate mofetil in children, adolescents, and adults with IgA nephropathy.
    Hogg RJ, Bay RC, Jennette JC, Sibley R, Kumar S, Fervenza FC, Appel G, Cattran D, Fischer D, Hurley RM, Cerda J, Carter B, Jung B, Hernandez G, Gipson D, Wyatt RJ.
    Am J Kidney Dis; 2015 Nov; 66(5):783-91. PubMed ID: 26209543
    [Abstract] [Full Text] [Related]

  • 4. Effects of Hydroxychloroquine on Proteinuria in IgA Nephropathy: A Randomized Controlled Trial.
    Liu LJ, Yang YZ, Shi SF, Bao YF, Yang C, Zhu SN, Sui GL, Chen YQ, Lv JC, Zhang H.
    Am J Kidney Dis; 2019 Jul; 74(1):15-22. PubMed ID: 30922594
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.
    Rovin BH, Barratt J, Heerspink HJL, Alpers CE, Bieler S, Chae DW, Diva UA, Floege J, Gesualdo L, Inrig JK, Kohan DE, Komers R, Kooienga LA, Lafayette R, Maes B, Małecki R, Mercer A, Noronha IL, Oh SW, Peh CA, Praga M, Preciado P, Radhakrishnan J, Rheault MN, Rote WE, Tang SCW, Tesar V, Trachtman H, Trimarchi H, Tumlin JA, Wong MG, Perkovic V, DUPRO steering committee and PROTECT Investigators.
    Lancet; 2023 Dec 02; 402(10417):2077-2090. PubMed ID: 37931634
    [Abstract] [Full Text] [Related]

  • 6. Effect of low-dose valsartan on proteinuria in normotensive immunoglobulin A nephropathy with minimal proteinuria: a randomized trial.
    Jo YI, Na HY, Moon JY, Han SW, Yang DH, Lee SH, Park HC, Choi HY, Lim SD, Kie JH, Lee YK, Shin SK.
    Korean J Intern Med; 2016 Mar 02; 31(2):335-43. PubMed ID: 26874511
    [Abstract] [Full Text] [Related]

  • 7. Tacrolimus decreases proteinuria in patients with refractory IgA nephropathy.
    Hu T, Liu Q, Xu Q, Liu H, Qiu W, Huang F, Zhang S, Lv Y.
    Medicine (Baltimore); 2018 May 02; 97(18):e0610. PubMed ID: 29718866
    [Abstract] [Full Text] [Related]

  • 8. Comparison of the effects of valsartan plus activated vitamin D versus valsartan alone in IgA nephropathy with moderate proteinuria.
    Xiaowei L, Bo W, Li L, Peng Z.
    Int Urol Nephrol; 2020 Jan 02; 52(1):129-136. PubMed ID: 31768803
    [Abstract] [Full Text] [Related]

  • 9. Valsartan combined with clopidogrel and/or leflunomide for the treatment of progressive immunoglobulin A nephropathy.
    Cheng G, Liu D, Margetts P, Liu L, Zhao Z, Liu Z, Tang L, Fang Y, Li H, Guo Y, Chen F, Liu F.
    Nephrology (Carlton); 2015 Feb 02; 20(2):77-84. PubMed ID: 25358874
    [Abstract] [Full Text] [Related]

  • 10. Corticosteroids or immunosuppressants were not superior to supportive care in IgA nephropathy patients with mild proteinuria.
    Pei G, Tan J, Tang Y, Tan L, Zhong Z, Zhou L, Chen C, Qin W.
    Medicine (Baltimore); 2020 Jun 12; 99(24):e20513. PubMed ID: 32541473
    [Abstract] [Full Text] [Related]

  • 11. The safety and short-term efficacy of aliskiren in the treatment of immunoglobulin a nephropathy--a randomized cross-over study.
    Szeto CC, Kwan BC, Chow KM, Leung CB, Li PK.
    PLoS One; 2013 Jun 12; 8(5):e62736. PubMed ID: 23675422
    [Abstract] [Full Text] [Related]

  • 12. Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy.
    Manno C, Torres DD, Rossini M, Pesce F, Schena FP.
    Nephrol Dial Transplant; 2009 Dec 12; 24(12):3694-701. PubMed ID: 19628647
    [Abstract] [Full Text] [Related]

  • 13. Long-term data on tacrolimus treatment in lupus nephritis.
    Yap DY, Ma MK, Mok MM, Kwan LP, Chan GC, Chan TM.
    Rheumatology (Oxford); 2014 Dec 12; 53(12):2232-7. PubMed ID: 24996908
    [Abstract] [Full Text] [Related]

  • 14. Tacrolimus improves the proteinuria remission in patients with refractory IgA nephropathy.
    Zhang Q, Shi SF, Zhu L, Lv JC, Liu LJ, Chen YQ, Zhang H, Wang HY.
    Am J Nephrol; 2012 Dec 12; 35(4):312-20. PubMed ID: 22456060
    [Abstract] [Full Text] [Related]

  • 15. Treatment effects of Chinese medicine (Yi-Qi-Qing-Jie herbal compound) combined with immunosuppression therapies in IgA nephropathy patients with high-risk of end-stage renal disease (TCM-WINE): study protocol for a randomized controlled trial.
    Li S, Li JP.
    Trials; 2020 Jan 06; 21(1):31. PubMed ID: 31907076
    [Abstract] [Full Text] [Related]

  • 16. Comparison of inhibitors of renin-angiotensin-aldosterone system (RAS) and combination therapy of steroids plus RAS inhibitors for patients with advanced immunoglobulin A nephropathy and impaired renal function.
    Moriyama T, Nakayama K, Ochi A, Amemiya N, Tsuruta Y, Kojima C, Itabashi M, Takei T, Uchida K, Nitta K.
    Clin Exp Nephrol; 2012 Apr 06; 16(2):231-7. PubMed ID: 22038185
    [Abstract] [Full Text] [Related]

  • 17. Combination therapy of low-dose cyclosporine and steroid in adults with IgA nephropathy
.
    Ihm HS, Lee JY, Hwang HS, Kim YG, Moon JY, Lee SH, Jeong KH, Lee TW, Ihm CG.
    Clin Nephrol; 2019 Sep 06; 92(3):131-140. PubMed ID: 31232271
    [Abstract] [Full Text] [Related]

  • 18. Optimal proteinuria target for renoprotection in patients with IgA nephropathy.
    Nam KH, Kie JH, Lee MJ, Chang TI, Kang EW, Kim DW, Lim BJ, Park JT, Kwon YE, Kim YL, Park KS, An SY, Oh HJ, Yoo TH, Kang SW, Choi KH, Jeong HJ, Han DS, Han SH.
    PLoS One; 2014 Sep 06; 9(7):e101935. PubMed ID: 25003873
    [Abstract] [Full Text] [Related]

  • 19. Combined Immunosuppressive Treatment May Improve Short-Term Renal Outcomes in Chinese Patients with Advanced IgA Nephropathy.
    Tan L, Tang Y, Peng W, Mathew BS, Qin W.
    Kidney Blood Press Res; 2018 Sep 06; 43(4):1333-1343. PubMed ID: 30099439
    [Abstract] [Full Text] [Related]

  • 20. The Association of Glomerular Glucocorticoid Receptor Expression with Responsiveness to Corticosteroid Treatment in IgA Nephropathy.
    Kee YK, Nam BY, Jhee JH, Park JT, Lim BJ, Yoo TH, Kang SW, Jeong HJ, Han SH.
    Am J Nephrol; 2019 Sep 06; 50(3):187-195. PubMed ID: 31408863
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.